Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Diberal

From Wikipedia, the free encyclopedia
(Redirected from(-)-5-(1,3-Dimethylbutyl)-5-ethylbarbituric acid)

Diberal[1]
Names
IUPAC name
5-ethyl-5-(4-methylpentan-2-yl)-1,3-diazinane-2,4,6-trione
Other names
  • DMBB
  • 5-Ethyl-5-(1,3-dimethylbutyl)barbituric acid
  • 5-(1,3-Dimethylbutyl)-5-ethylbarbituric acid
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C12H20N2O3/c1-5-12(8(4)6-7(2)3)9(15)13-11(17)14-10(12)16/h7-8H,5-6H2,1-4H3,(H2,13,14,15,16,17)
    Key: KXHLANWWTKSOMW-UHFFFAOYSA-N
  • CCC1(C(=O)NC(=O)NC1=O)C(C)CC(C)C
Properties
C12H20N2O3
Molar mass240.303 g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

Diberal, also known as5-(1,3-Dimethylbutyl)-5-ethylbarbituric acid orDMBB, is an atypicalbarbiturate. This compound can be eitherconvulsant oranticonvulsant depending on which enantiomer is used.

Pharmacology

[edit]

Diberal, unlike mostbarbiturates, can have convulsant actions. This is uncommon, as barbiturates typically enhance the function ofGABA asallorestic modulators andagonists (at higher doses),[2] therefore havinganticonvulsant properties. Depending on which isomer is used, it can have eitherconvulsant or anticonvulsant actions.

The different pharmacological profile betweenisomers is thought to be due to the differences in the formation ofhydrogen bonds at the binding sites.[3]

(+)-Isomer

[edit]

(+)-DMBB is the atypical enantiomer of diberal. It is atypical in the means that it has convulsant action, unlike most barbiturate drugs.[4]

(−)-Isomer

[edit]

Unlike (+)-DMBB, the (−)-isomer is similar to most barbiturates by having anticonvulsant action. It has been found that administration of (−)-DMBB reverses the convulsant actions of (+)-DMBB.[3] (−)-DMBB is slightly more potent thanpentobarbital in its depressant properties.[5]

See also

[edit]

References

[edit]
  1. ^"Diberal".PubChem. U.S. National Library of Medicine.
  2. ^Suddock JT, Kent KJ, Regina AC, Cain MD (2024)."Barbiturate Toxicity".StatPearls. Treasure Island (FL): StatPearls Publishing.PMID 29763050.
  3. ^abHo IK, Harris RA (1981)."Mechanism of action of barbiturates"(PDF).Annual Review of Pharmacology and Toxicology.21:83–111.doi:10.1146/annurev.pa.21.040181.000503.PMID 6263177.
  4. ^Desai R, Savechenkov PY, Zolkowska D, Ge RL, Rogawski MA, Bruzik KS, et al. (November 2015)."Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the α1 β3 γ2L GABAA receptor account for their in vivo effects".The Journal of Physiology.593 (22):4943–4961.doi:10.1113/JP270971.PMC 4650410.PMID 26378885.
  5. ^Downes H, Perry RS, Ostlund RE, Karler R (December 1970)."A study of the excitatory effects of barbiturates".The Journal of Pharmacology and Experimental Therapeutics.175 (3):692–699.PMID 5489924.
GABA receptor antagonists
GABA synthesis inhibitors
Glycine receptor antagonists
Glutamate receptor agonists
Convulsantbarbiturates
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=Diberal&oldid=1258330522"
Category:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp